Research · Sep 3, 2026
[VTRS] Viatris Thesis 2026: Biosimilars and Ophthalmology Pivot Tests Generic Cycle Stabilization
Viatris Inc. (NASDAQ: VTRS) FY2025 revenue ~$13.5-14B (-3 to 0%) with adj. EPS ~$2.10-2.60 reflecting continued post-November 2020 Pfizer Upjohn + Mylan merger debt deleveraging completion (~$10B+ debt reduction since merger; net debt $13-14B FY2025 vs ~$25B at merger) + selected biosimilars portfolio ($700M-1B revenue including Hulio + Semglee + Ogivri + Fulphila) + selected post-2024 strategic refocus on biosimilars + ophthalmology under new CEO Scott Smith (ex-Bausch + Lomb CEO bringing ophthalmology specialty pharma expertise). Leading global generic + branded pharmaceutical firm formed via November 2020 merger of Pfizer's Upjohn (off-patent branded pharmaceutical business) + Mylan N.V. (generic pharmaceutical leader). Selected post-merger consolidated entity creating ~$17B+ revenue baseline + ~$25B initial debt + ~50K+ employees globally. Headquartered in Canonsburg Pennsylvania + Pittsburgh Pennsylvania (dual headquarters); ~38,000+ employees globally with ~$13.5-14B revenue. Four reporting segments: Developed Markets ~50% revenue ($7B — US + EU + Japan brand + generic including historic Pfizer Upjohn brands Lipitor + Norvasc + Lyrica + Viagra + selected generics), Greater China ~10% ($1.4B — China brand + generic), Emerging Markets ~25% ($3.5B — Russia + Brazil + Turkey + Middle East + Africa generics + brand), JANZ ~15% ($2B — Japan + Australia + New Zealand brand + generic; post-2020 Pfizer Upjohn JANZ contribution). Biosimilars pivot: ~$700M-1B FY2025 biosimilars revenue (Hillrom Mylan + Biocon biosimilars partnerships since 2009; major biosimilars Hulio adalimumab biosimilar Humira biosimilar ~$300M+ + Semglee insulin glargine biosimilar Lantus biosimilar ~$200M+ + Ogivri trastuzumab biosimilar Herceptin biosimilar ~$150M+ + Fulphila pegfilgrastim biosimilar Neulasta biosimilar ~$100M+); ~$50-100B+ global biosimilars TAM growing 15-20% annually; FY2026 expected biosimilars toward $1.0-1.3B (+30-40%). Ophthalmology pivot: post-2024 strategic refocus reflected in new CEO Scott Smith appointment (ex-Bausch + Lomb CEO); ~$1B+ FY2025 ophthalmology portfolio (post-2023 Idorsia Pivlaz + selected post-2024 Idorsia ophthalmology portfolio acquisitions + internal development); ophthalmology growth ~10-15% YoY; FY2026 catalyst: continued ophthalmology pipeline + selected $1.5-2B ophthalmology revenue trajectory. CEO Scott Smith since April 2024 (succeeded Michael Goettler CEO November 2020-April 2024 retired who led 2020-2024 post-merger integration + debt deleveraging; Smith ex-Bausch + Lomb CEO 2017-2024 + ex-Bausch Health Companies + selected ophthalmology + dermatology specialty pharma + ~30-year career). Capital return: ~$0.48-0.50 annual dividend FY2025 (~$0.12/quarter; ~3+ year track since November 2020 merger); $1-2B buyback program FY2025 (aggressive post-deleveraging); investment-grade Baa3/BBB- credit ratings; FCF $2-2.5B; net debt $13-14B (vs $25B at merger). FY2026 thesis: biosimilars +30-40% + ophthalmology pivot + ~5-year dividend track + continued debt deleveraging. Risks: major Hulio/Semglee/Ogivri competitive substitution, ophthalmology pipeline failure, Developed Markets continued LOE cycle, FX headwinds.